Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon α for chronic hepatitis C-Reference-Cited by-同舟云学术

Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon α for chronic hepatitis C

Published:2003-07 Issue:1 Volume:39 Page:106-111
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Zeuzem Stefan,Heathcote E.Jenny,Shiffman Mitchell L,Wright Teresa L,Bain Vincent G,Sherman Morris,Feinman S.Victor,Fried Michael W,Rasenack Jens,Sarrazin Christoph,Jensen Donald M,Lin Amy,Hoffman Joseph H,Sedarati Farhad

Publisher

Elsevier BV

Subject

Hepatology

Reference20 articles.

1. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team;Alter;N Engl J Med,1992

2. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma;Saito;Proc Natl Acad Sci USA,1990

3. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon;Reichard;J Hepatol,1999

4. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy;Marcellin;Ann Intern Med,1997

5. Durability of viral response to interferon alone or in combination with oral ribavirin in patients with chronic hepatitis C;Davis;Hepatology,1999

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Four weeks of off‐treatment follow‐up is sufficient to determine virologic responses at off‐treatment week 12 in patients with hepatitis C virus infection receiving fixed‐dose pangenotypic direct‐acting antivirals;Journal of Medical Virology;2024-05

2. Four weeks of off-treatment follow-up is sufficient to determine virologic responses at off-treatment week 12 in patients with hepatitis C virus infection receiving pangenotypic direct-acting antivirals;2024-01-23

3. Comparison of the efficacy and safety of direct-acting antiviral agents in the treatment of hepatitis C virus genotype 1 between the Turkish elderly and younger population;The Turkish Journal of Geriatrics;2022-03-31

4. Evaluation of Glycated Haemoglobin (HbA1c) Level in Type 2 Diabetic Chronic HCV Non-cirrhotic Treatment-Naïve Egyptian Patients Eradicated with Sofosbuvir Plus Daclatasvir;Current Diabetes Reviews;2020-01-21

5. Sustained virological response 12 versus sustained virological response 24 as evaluation endpoints in chronic hepatitis C virus Egyptian patients treated with sofosbuvir-based regimens;The Egyptian Journal of Internal Medicine;2019-12